Sign up
Pharma Capital

Genedrive kicks off first commercial sales and shipments of HCV ID Kit

David Budd, chief executive of Genedrive PLC (LON:GDR), tells Proactive they've begun commercial sales and shipments of their Genedrive HCV ID Kit, a qualitative molecular assay for HCV and Genedrive platform into the EMEA region - with an initial focus on Africa.

The products have been shipped to their distributor, Sysmex Corporation, a world leader in clinical laboratory systemisation and solutions, and are now destined for use in various initial target countries.

Budd adds that first commercial sales and shipments of the HCV ID kit and platform are expected to commence in the Asia Pacific region in the coming weeks.


View full GDR profile View Profile
CN Video

Riccardo Lowi discusses Genedrive Plc

View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.